Lixisenatide — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 4 sources[1,2,3,4].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Lixisenatide in patients with type 2 diabetes and acute coronary syndrome | New England Journal of Medicine | 2015 |
| 2 | Mechanisms of action and therapeutic application of glucagon-like peptide-1 | Cell Metabolism | 2018 |
| 3 | GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art | Molecular Metabolism | 2021 |
| 4 | Related impurities in peptide medicines | Journal of Pharmaceutical and Biomedical Analysis | 2014 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 23 | GETGOAL-M · GETGOAL-L · GETGOAL-DUO-1 · ELIXA · GETGOAL-M-BIOMARKER · GETGOAL-L-PK · GETGOAL-DUO-1-HEPATIC-IMP · ELIXA-DDI · GETGOAL-M-ADHERENCE · GETGOAL-L-RENAL-IMP · GETGOAL-DUO-1-DDI · ELIXA-HEPATIC-IMP · GETGOAL-M-OLE · GETGOAL-L-HEPATIC-IMP and 9 more |
| Evidence syntheses | 4 | Cardiovascular outcomes with glucagon-like peptide-1… · Lixisenatide in type 2 diabetes mellitus: effect on the… · Lixisenatide in type 2 diabetes mellitus: tolerability and… · Lixisenatide in type 2 diabetes mellitus: durability of… |
| Comment periods | 1 | Draft monograph: Lixisenatide |
| Indication assessments | 3 | Type 2 diabetes · Cardiovascular · Obesity |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225 · PMID 26630143
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001 · PMID 29617641
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Molecular Metabolism 2021;46:101102. doi:10.1016/j.molmet.2020.101102 · PMID 33068776
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.